Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the markets.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.
UTHR
$500+Infinity%1D
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 520.00 USD with a low forecast of 423.00 USD and a high forecast of 600.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 520.00 USD with a low forecast of 423.00 USD and a high forecast of 600.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 500.300
Low
423.00
Averages
520.00
High
600.00
Current: 500.300
Low
423.00
Averages
520.00
High
600.00
UBS
Buy
maintain
$580 -> $600
2025-11-06
Reason
UBS
Price Target
$580 -> $600
2025-11-06
maintain
Buy
Reason
UBS raised the firm's price target on United Therapeutics to $600 from $580 and keeps a Buy rating on the shares.
Morgan Stanley
Equal Weight
maintain
$435 -> $447
2025-10-30
Reason
Morgan Stanley
Price Target
$435 -> $447
2025-10-30
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on United Therapeutics to $447 from $435 and keeps an Equal Weight rating on the shares. Despite a Q3 miss, shares traded up following commentary on the call regarding the potential for a Tyvaso rest-of-the-world partnerships following recent Phase 3 IPF data, the analyst noted. During the post Q3 follow up call, management noted that the commentary was meant to suggest that the company is open to partnerships and collaborations, but that there are no active discussions, the analyst tells investors.
RBC Capital
Lisa Walter
Outperform
maintain
$569 -> $587
2025-10-30
Reason
RBC Capital
Lisa Walter
Price Target
$569 -> $587
2025-10-30
maintain
Outperform
Reason
RBC Capital analyst Lisa Walter raised the firm's price target on United Therapeutics to $587 from $569 and keeps an Outperform rating on the shares. The company's Q3 results support the firm's view that Tyvaso will continue to grow irrespective of new market entrants, IPF could double the top-line to over $6B in the next 5 years, and the base business will show resiliency, the analyst tells investors in a research note.
H.C. Wainwright
Andrew Fein
Buy
maintain
$500 -> $525
2025-10-30
Reason
H.C. Wainwright
Andrew Fein
Price Target
$500 -> $525
2025-10-30
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on United Therapeutics to $525 from $500 and keeps a Buy rating on the shares following the Q3 report. The firm cites Tyvaso revenue growth and the "strong" early launch of Yutrepia for the target boost.
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
